• Viridian Therapeutics recently announced that the FDA has accepted its Biologics License Application for thyroid eye disease drug veligrotug, granting Priority Review with a target decision date of June 30, 2026, while the company also progresses a European filing and pivotal phase 3 trials for elegrobart (VRDN-003).
• This cluster of regulatory milestones meaningfully advances Viridian’s thyroid eye disease franchise, concentrating attention on how its pipeline could reshape treatment options for patients.
• Next, we’ll examine how the Priority Review for veligrotug influences Viridian’s investment narrative and the risk-reward profile around upcoming milestones.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Viridian Therapeutics' Investment Narrative?

To own Viridian today, you need to believe its thyroid eye disease franchise can translate strong clinical and regulatory momentum into a sustainable commercial business, despite the company still being loss making and trading on a rich sales multiple. The FDA’s Priority Review for veligrotug, with a June 30, 2026 decision date, pulls a major catalyst into clearer focus and helps explain the recent share price strength, but it does not remove key execution risks around launch readiness, pricing, and payer uptake if approval comes. At the same time, upcoming phase 3 readouts for elegrobart in early 2026 now look even more important, because they could define Viridian’s competitiveness in subcutaneous therapy and influence future financing needs, especially after recent equity raises and royalty monetization deals.

However, this faster regulatory timeline also sharpens one risk many shareholders may be underestimating. Viridian Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly US$0.18 to US$157.60 per share, underlining how far apart individual models can land. Set against Viridian’s rich valuation and binary 2026 trial and FDA catalysts, this spread shows why it can help to weigh several perspectives before forming a view on the company’s prospects.

Explore 3 other fair value estimates on Viridian Therapeutics - why the stock might be worth over 4x more than the current price!

Build Your Own Viridian Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Viridian Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viridian Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viridian Therapeutics' overall financial health at a glance.

No Opportunity In Viridian Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.